CN105143441A - 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 - Google Patents
用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 Download PDFInfo
- Publication number
- CN105143441A CN105143441A CN201480017697.1A CN201480017697A CN105143441A CN 105143441 A CN105143441 A CN 105143441A CN 201480017697 A CN201480017697 A CN 201480017697A CN 105143441 A CN105143441 A CN 105143441A
- Authority
- CN
- China
- Prior art keywords
- cell
- lymphocyte
- culture
- cells
- ghost
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 223
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 52
- 238000000338 in vitro Methods 0.000 title abstract description 33
- 238000005406 washing Methods 0.000 claims abstract description 24
- 210000000822 natural killer cell Anatomy 0.000 claims description 84
- 239000000243 solution Substances 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 239000006285 cell suspension Substances 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 12
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 10
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 9
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 9
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 8
- 108090000172 Interleukin-15 Proteins 0.000 claims description 8
- 238000005336 cracking Methods 0.000 claims description 8
- 239000000815 hypotonic solution Substances 0.000 claims description 8
- 239000000644 isotonic solution Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 229930182566 Gentamicin Natural products 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 210000003289 regulatory T cell Anatomy 0.000 claims description 5
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 4
- 108090000695 Cytokines Proteins 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000003321 amplification Effects 0.000 description 67
- 238000003199 nucleic acid amplification method Methods 0.000 description 67
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 61
- 241001637516 Polygonia c-album Species 0.000 description 42
- 230000000694 effects Effects 0.000 description 26
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 18
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 102000002627 4-1BB Ligand Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- -1 IL-7 Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000003526 lymphopoietic effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VOAXAOULFRTTAM-UHFFFAOYSA-N chloroform phenol Chemical compound C1(=CC=CC=C1)O.C(Cl)(Cl)Cl.C1(=CC=CC=C1)O.C1(=CC=CC=C1)O VOAXAOULFRTTAM-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1164—NK cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (12)
- 权利要求书1、 一种制备细胞空壳的方法, 其特征在于, 包括:将细胞进行洗涤处理, 以便获得经过洗涤的细胞;将所述经过洗涤的细胞进行裂解处理, 以便获得细胞空壳;其中, 所述细胞的表面具有能够促进淋巴细胞增殖分化的细胞因子。
- 2、 根据权利要求 1所述的方法, 其特征在于, 所述洗涤处理进一步包括:将所述细胞悬浮于等渗溶液中, 以便获得细胞悬液;将所述细胞悬液进行离心处理, 以便获得所述经过洗涤的细胞。
- 3、 根据权利要求 2所述的方法, 其特征在于, 在将所述细胞悬浮于等渗溶液中之前, 预先将所述等渗溶液预冷至 4摄氏度。4、 根据权利要求 3所述的方法, 其特征在于, 所述等渗溶液为 pH为 7.4的等渗磷酸 盐缓冲液。
- 5、 根据权利要求 1所述的方法, 其特征在于, 所述裂解处理进一步包括:按照预定体积比例将所述经过洗涤的细胞悬浮于低渗溶液中, 将所得到的细胞悬液静 置 2小时, 以便获得细胞裂解物;将所述细胞裂解物进行离心处理, 以便获得所述细胞空壳。
- 6、 根据权利要求 5所述的方法, 其特征在于, 所述预定体积比例为 1 : 40。
- 7、 根据权利要求 5所述的方法, 其特征在于, 在将所述经过洗涤的细胞悬浮于低渗溶 液中之前, 预先将所述低渗溶液预冷至 4摄氏度。
- 8、 根据权利要求 7所述的方法, 其特征在于, 所述低渗溶液为低渗 Tris盐酸缓冲液。
- 9、 根据权利要求 1所述的方法, 其特征在于, 所述能够促进淋巴细胞增殖活化的细胞 因子为选自 IL-4、 IL-7、 IL-15、 IL-21、 CD19、 CD64、 CD86和 4-1BBL中的至少一种。
- 10、 一种细胞空壳, 其特征在于, 所述细胞空壳是通过权利要求 1-9任一项所述的方 法制备的。
- 11、 一种培养淋巴细胞的方法, 其特征在于, 包括:将所述淋巴细胞与液体培养基混合, 以便得到淋巴细胞悬浮液;将所述淋巴细胞悬浮液加入到培养容器中, 并向所述培养容器中加入权利要求 10所述 的细胞空壳; 以及将所述培养容器在饱和湿度、 温度为 37摄氏度以及二氧化碳浓度为 5.0体积%的培养 箱中进行培养。
- 12、 根据权利要求 11所述的方法, 其特征在于, 所述淋巴细胞包括 NK细胞、 CTL细 胞和 Treg细胞。 13、 根据权利要求 12所述的方法, 其特征在于, 所述淋巴细胞悬浮液中含有 40毫升 液体培养基以及 5 X 10<sup>6</sup>个所述淋巴细胞, 所述细胞空壳与所述淋巴细胞的比例为 1 : 1。
- 14、 一种扩增活化淋巴细胞的方法,其特征在于, 包括:( 1 ) 从人外周血中分离单核细胞;(2) 将步骤 (1 ) 中所分离的单核细胞与 40ml淋巴细胞培养液混合, 以便获得淋巴 细胞悬浮液,其中,所述淋巴细胞培养液为含有 200 IU/ml IL-2、 1体积%自体血浆和 80U/ml 庆大霉素的 PMI1640完全培养液, 所述 40 ml淋巴细胞悬浮液中含有 5 X 106个所述单核细 胞;(3 ) 将步骤 (2) 中所得到的所述淋巴细胞悬浮液加入到 T175 培养瓶中, 并向所述T175培养瓶中加入 5 X 106个权利要求 10所述的细胞空壳, 并置于培养箱中,在饱和湿度、 37°C以及 5.0体积% C02的条件下进行培养;(4) 在所述培养的第四天, 补加 40ml RPMI 1640完全培养液;(5 ) 在所述培养的第七天, 将所述 T175培养瓶中的细胞转移到培养袋中, 补加所述 完全培养液至 400ml, 并添加 8 X 107个权利要求 10所述的细胞空壳;(6)在所述培养的第十天, 将培养物传代至两个培养袋中, 其中, 每个培养袋中含有 640ml所述完全培养液; 以及(7) 在所述培养的第十二天, 收集培养产物, 以便获得淋巴细胞,其中, 所述淋巴细胞包括 NK细胞、 CTL细胞和 Treg细胞。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/070545 WO2015103793A1 (zh) | 2014-01-13 | 2014-01-13 | 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105143441A true CN105143441A (zh) | 2015-12-09 |
CN105143441B CN105143441B (zh) | 2019-11-08 |
Family
ID=53523482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480017697.1A Active CN105143441B (zh) | 2014-01-13 | 2014-01-13 | 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9796960B2 (zh) |
CN (1) | CN105143441B (zh) |
WO (1) | WO2015103793A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105505870A (zh) * | 2016-01-20 | 2016-04-20 | 深圳市中美康士生物科技有限公司 | 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途 |
CN110358736A (zh) * | 2016-05-20 | 2019-10-22 | 杭州优善生物科技有限公司 | 一种修饰的k562细胞、其制备方法及nk细胞培养组合物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107109363A (zh) * | 2015-11-09 | 2017-08-29 | 张明杰 | 增强对异常细胞杀伤力的方法和药物组合物 |
CN109153974A (zh) * | 2016-03-04 | 2019-01-04 | 张明杰 | 增强对异常细胞杀伤力的组合物及其应用 |
CA3090096A1 (en) * | 2018-01-30 | 2019-08-08 | Research Institute At Nationwide Children's Hospital | Transforming growth factor beta-resistant natural killer cells |
CN110331132B (zh) * | 2019-08-09 | 2021-08-24 | 侯宗柳 | 一种体外大规模诱导nk细胞扩增的方法 |
CN112553157B (zh) * | 2020-12-23 | 2023-07-07 | 杭州中赢生物医疗科技有限公司 | 一种淋巴细胞的扩增体系及扩增方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102596179A (zh) * | 2009-08-27 | 2012-07-18 | 工业研究与发展基金会有限公司 | 脂质体组合物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102224237B (zh) * | 2008-01-18 | 2014-03-12 | 沃纳·卢比茨 | 使用β-丙内酯(BLP)进行最终灭活的细菌菌影(BG)生产方法 |
CN102433303B (zh) * | 2011-12-29 | 2013-02-20 | 辽宁迈迪生物科技有限公司 | 用于t淋巴细胞的体外培养方法 |
-
2014
- 2014-01-13 CN CN201480017697.1A patent/CN105143441B/zh active Active
- 2014-01-13 US US15/106,985 patent/US9796960B2/en active Active
- 2014-01-13 WO PCT/CN2014/070545 patent/WO2015103793A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102596179A (zh) * | 2009-08-27 | 2012-07-18 | 工业研究与发展基金会有限公司 | 脂质体组合物及其用途 |
Non-Patent Citations (3)
Title |
---|
LARRY E. WESTERMAN AND PETER E. JENSEN: "Liposomes Composed of Reconstituted Membranes for Induction of Tumor-Specific Immunity", 《LIPOSOMES IN IMMUNOLOGY》 * |
MICHAEL HEIKE, ET AL: "Membranes activate tumor- and virus-specific precursor cytotoxic T lymphocytes in vivo and stimulate tumor-specific T lymphocytes in vitro: implications for vaccination.Michael Heike et al,", 《JOURNAL OF IMMUNOTHERAPY》 * |
PIERRE A. HENKART: "MECHANISM OF LYMPHOCYTE-MEDIATED CYTOTOXICITY!", 《ANN. REV.LMMUNOL》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105505870A (zh) * | 2016-01-20 | 2016-04-20 | 深圳市中美康士生物科技有限公司 | 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途 |
CN105505870B (zh) * | 2016-01-20 | 2017-07-25 | 深圳市中美康士生物科技有限公司 | 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途 |
CN110358736A (zh) * | 2016-05-20 | 2019-10-22 | 杭州优善生物科技有限公司 | 一种修饰的k562细胞、其制备方法及nk细胞培养组合物 |
CN110358736B (zh) * | 2016-05-20 | 2023-07-07 | 杭州朔溪生物医药有限公司 | 一种修饰的k562细胞、其制备方法及nk细胞培养组合物 |
Also Published As
Publication number | Publication date |
---|---|
US9796960B2 (en) | 2017-10-24 |
CN105143441B (zh) | 2019-11-08 |
WO2015103793A1 (zh) | 2015-07-16 |
US20170037371A1 (en) | 2017-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105143441A (zh) | 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法 | |
US20230203444A1 (en) | Method of culturing nk cells and kits containing medium additions | |
Castellino et al. | Chemokine-guided CD4+ T cell help enhances generation of IL-6RαhighIL-7Rαhigh prememory CD8+ T cells | |
CN1738619B (zh) | 给予体外部分成熟的树突细胞治疗肿瘤的制药用途 | |
CN108220235A (zh) | 一种体外活化扩增人自然杀伤(nk)细胞的方法及其专用培养体系 | |
CN108348550A (zh) | 用于表达嵌合抗原受体和其它受体的t细胞 | |
CN101385742A (zh) | 来自人类血液的cd4+cd25+调节性t细胞 | |
JP2011529341A (ja) | ナチュラルキラー細胞の増殖方法 | |
US11566227B2 (en) | Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same | |
CN102973928A (zh) | 引发单核树突细胞和t细胞th-1应答的组合物和方法 | |
CN101302491A (zh) | 高效扩增活化淋巴细胞的方法和培养系统 | |
CN102669087A (zh) | 一种外周血单个核细胞的冻存液及冻存方法 | |
CN104498434B (zh) | 一种大量树突状细胞的制备方法、所得树突状细胞 | |
CN105349489A (zh) | 一种cik细胞的培养方法 | |
US11944672B2 (en) | Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying Treg cells to produce therapeutic vaccine for treatment of diabetes type 1 | |
CN105994254A (zh) | 一种dc细胞的冻存液及冻存方法 | |
CN105886470A (zh) | 一种扩增nk细胞的方法 | |
CN104152411A (zh) | 一种自体树突状细胞激活肿瘤浸润性t淋巴细胞的制备方法及其应用 | |
CN103981144B (zh) | 自体血清抗原致敏dc‑cik细胞的制备方法 | |
KR101900807B1 (ko) | 헬퍼 t1 특성들 및 세포용해 특성들을 발현하는 세포들 | |
CN106795492A (zh) | 一种肿瘤特异性ctl的制备方法 | |
Van Bekkum et al. | The effect of pretreatment of allogeneic bone marrow graft recipients with antilymphocytic serum on the acute graft-versus-host reaction in monkeys | |
CN105051183B (zh) | 保藏淋巴细胞体外培养增效剂的方法 | |
Le et al. | Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting | |
KR20220031462A (ko) | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160226 Address after: Paul Street 518004 Shenzhen Road, Guangdong, Luohu District No. 72 Liantang high tech Park 119 first floor of Building 5 Applicant after: Zhang Mingjie Address before: Paul Street 518004 Shenzhen Road, Guangdong, Luohu District No. 72 Liantang high tech Park 119 first floor of Building 5 Applicant before: SHENZHEN HANK BIOLOG ENGINEERING CO LTD |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200119 Address after: Paul Street 518004 Shenzhen Road, Guangdong, Luohu District No. 72 Liantang high tech Park 119 first floor of Building 5 Patentee after: SHENZHEN HANK BIOLOG ENGINEERING CO LTD Address before: Paul Street 518004 Shenzhen Road, Guangdong, Luohu District No. 72 Liantang high tech Park 119 first floor of Building 5 Patentee before: Zhang Mingjie |
|
TR01 | Transfer of patent right |